Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfasalazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.57 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.57 |
| ▸ | SLC7A11 | Q9UPY5 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MMP1 | P03956 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfasalazine SCHEMBL29861725 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL18256143 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL487664 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL31174674 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL5664970 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL10289061 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL4515 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL20994010 | 0.99 | SLC7A11 (0.98) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL21055748 | 0.99 | SLC7A11 (0.98) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL5930194 | 0.99 | SLC7A11 (0.98) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 83422 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| WO-2026105679-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR SKIN DISORDER | 国立大学法人神戸大学 | 2026-05-21 | — | — | WO | claimed |
| WO-2026103879-A1 | USE OF BIPHENYL-CONTAINING COMPOUND FOR TREATING INFLAMMATORY BOWEL DISEASE | 正大天晴药业集团股份有限公司 | 2026-05-21 | — | — | WO | claimed |
| US-20260137671-A1 | PDK4 as a Cell-Aging Intervention Target and Its Use in Chemotherapy and Anticancer | SHANGHAI INST OF NUTRITION AND HEALTH CHINESE ACADEMY OF SCIENCES (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | claimed |
| WO-2026101558-A1 | ULTRAPURIFIED PHOSPHOLIPOPROTEOMIC COMPOSITION FOR HIGH-PURITY BIOMOLECULAR RESEARCH AND PRECISION THERAPEUTICS | AETHERION GLOBAL LLC (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260132191-A1 | METHODS FOR MODULATING ACTIVITY OF IL-18 FOR TREATMENT OF CD4+ T CELL MEDIATED AUTOIMMUNITY AND IMMUNOPATHOLOGY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739299-A1 | MODELS OF CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| EP-0364559-A1 | SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS. | SCRIPPS CLINIC RES (US) | 1990-04-25 | — | — | EP | claimed |
| WO-1990002546-A1 | PHARMACEUTICALS MICROENCAPSULATED BY VAPOR DEPOSITED POLYMERS AND METHOD | THE RONALD T. DODGE COMPANY (US) | 1990-03-22 | — | — | WO | claimed |
| US-4904474-A | Delivery of drug to colon by oral disage form | ALZA CORPORATION (US) | 1990-02-27 | — | — | US | claimed |
| EP-0352746-A2 | A composition for enhancing oxygen availability or relieving hypoxia in a mammal | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1990-01-31 | — | — | EP | claimed |
| WO-1989008658-A1 | SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-09-21 | — | — | WO | claimed |
| WO-1989008119-A1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTI-INFLAMMATORY DRUGS | SELCH LARSEN CLAUS (DK) | 1989-09-08 | — | — | WO | claimed |
| EP-0331471-A1 | High molecular weight prodrug derivatives of antiinflammatory drugs | Larsen, Claus Selch (DK) | 1989-09-06 | — | — | EP | claimed |
| US-4849416-A | ANTIHYPOXIC AGENTS, HETEROCYCLIC SULFONAMIDO AZO COMPOUND | RORER PHARMACEUTICAL CORPORATION (US) | 1989-07-18 | — | — | US | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |